• Mashup Score: 0
    Webprogram Unavailable - 5 month(s) ago

    Please click HERE if you are not redirected in 5

    Tweet Tweets with this article
    • Multiomics Profiling of Measurable Residual Disease (MRD) for Understanding the Biology of Ultra-Drug Resistance in Multiple Myeloma (MM) [Dec 10, 2022] @camilagdeblois et al. Abst 99 #ASH22 https://t.co/izMBdiswlP #mmsm #mmMRD https://t.co/Pqd9dhwohw

  • Mashup Score: 0
    Webprogram Unavailable - 5 month(s) ago

    Please click HERE if you are not redirected in 5

    Tweet Tweets with this article
    • Global Treatment Standard in Multiple Myeloma Remains Elusive: Updated Results from the INSIGHT MM Global, Prospective, Observational Study [Dec 10, 2022] @NoemiPuigM et al. @BerdejaJesus Abs 1859 #ASH22 https://t.co/mCCkPgMebV #mmsm #globonc https://t.co/JkTBMSg0au

  • Mashup Score: 0

    Talquetamab “demonstrated robust effic acy and manageable safety” in patients with heavily pretreated relapsed or refractory multiple myeloma, according to results from the phase I/II MonumenTAL-1 study. Ajai Chari, MD, of Mount Sinai School of Medicine, presented the data on talquetamab, a bispecific antibody targeting CD3 and GPRC5D, during the 2022 American Society of Hematology (ASH) Annual Meeting. “The MonumenTAL-1 study is really exciting,” Dr. Chari said, noting the phase I portion of the study

    Tweet Tweets with this article
    • Looking back at MounmenTAL-1? Don't miss our previous coverage of the talquetamab data presented at #ASCO2023 and #ASH22! In this video interview, @AjaiChari of @UCSF speaks about the results he presented at #ASH22. 📺https://t.co/G87ZRythZ4 #mmsm https://t.co/7Bzn4YpL1s

  • Mashup Score: 0

    Inotuzumab, GMALL, Ponatinib & Blinatumomab ASH Updates in Acute Lymphoblastic Leukemia By Van Huynh, MD Updates in acute lymphoblastic leukemia that was presented at ASH in New Orleans. So I think there were so many great talks. There were so many great talks and I decided I would focus on just three and really…

    Tweet Tweets with this article
    • 🚀 #ASH22 Updates in ALL Immunotherapy with Inotuzumab! Van Huynh, MD @MOASC_Office @UCIrvineHealth, shared insights at #MOASC23. 🩺 Discover remarkable breakthroughs![Video]🎥: https://t.co/BBlUqPvBAS 💊 #oncology #leukemia #medicalresearch #Immunotherapy #UCIMedSchool #CARTcell https://t.co/OSKdxJCTLI